| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/13696998.2016.1209508 |
| P698 | PubMed publication ID | 27376404 |
| P50 | author | Paulo Gustavo Kotze | Q51713860 |
| P2093 | author name string | James Signorovitch | |
| Mirhelen Mendes de Abreu | |||
| Jingdong Chao | |||
| Martha Skup | |||
| Dendy Macaulay | |||
| Yanjun Bao | |||
| Namita Tundia | |||
| Leonardo Chaves | |||
| Jorge Rojas Serrano | |||
| P2860 | cites work | Catastrophic health expenses and impoverishment of households of patients with rheumatoid arthritis. | Q48427619 |
| Societal cost of rheumatoid arthritis patients in the US. | Q48956161 | ||
| Basic epidemiology of inflammatory bowel disease in Puerto Rico | Q49235545 | ||
| Employer model of workplace impacts of anti-TNF therapy for rheumatoid arthritis. | Q51137094 | ||
| Work disability is related to the presence of arthritis and not to a specific diagnosis. Results from a large early arthritis cohort in Argentina. | Q51770477 | ||
| Indirect costs of rheumatoid arthritis in Brazil. | Q51878626 | ||
| Costs of work-related musculoskeletal disorders (MSDs) in developing countries: Colombia case. | Q53213935 | ||
| 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis | Q26828418 | ||
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update | Q26859134 | ||
| Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry). | Q33453053 | ||
| Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study | Q33540305 | ||
| Treating rheumatoid arthritis to target: recommendations of an international task force | Q34462557 | ||
| Management of Crohn's disease in adults. | Q34931424 | ||
| Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: a meta-analysis | Q35452972 | ||
| Health care resource use and costs in Crohn's disease before and after infliximab therapy | Q35452992 | ||
| The costs of Crohn's disease in the United States and other Western countries: a systematic review | Q37027650 | ||
| Challenges in the management of rheumatoid arthritis in developing countries. | Q37265648 | ||
| Economic evaluation guidelines in Latin America: a current snapshot | Q37800479 | ||
| The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management | Q37814541 | ||
| Current therapies in rheumatoid arthritis: a Latin American perspective. | Q38075662 | ||
| Hispanics and inflammatory bowel disease | Q38315646 | ||
| Development of a conceptual model evaluating the humanistic and economic burden of Crohn's disease: implications for patient-reported outcomes measurement and economic evaluation | Q38488635 | ||
| Biosimilars for the management of rheumatoid arthritis: economic considerations | Q38591281 | ||
| Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of São Paulo State, Brazil | Q39886075 | ||
| The prevalence of rheumatoid arthritis in Argentina: a capture-recapture study in a city of Buenos Aires province. | Q39951793 | ||
| Unemployment and disability in patients with moderately to severely active Crohn's disease | Q40432386 | ||
| Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology | Q44058082 | ||
| Changes in utilization and costs for patients with rheumatoid arthritis, 1997 to 2006. | Q44253853 | ||
| Influence of rheumatoid arthritis on employment, function, and productivity in a nationally representative sample in the United States | Q44650428 | ||
| The direct and indirect cost burden of Crohn's disease and ulcerative colitis | Q44898963 | ||
| Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. | Q47827799 | ||
| Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience | Q48314202 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Argentina | Q414 |
| rheumatoid arthritis | Q187255 | ||
| Crohn's disease | Q1472 | ||
| P304 | page(s) | 1187-1199 | |
| P577 | publication date | 2016-07-19 | |
| P1433 | published in | Journal of Medical Economics | Q6295521 |
| P1476 | title | Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico | |
| P478 | volume | 19 |
| Q91629109 | Biosimilar Drugs: What Would Be a Reasonable Extrapolation? |
| Q91004089 | Economic Benefit of Sponsored Controlled Clinical Trials: The Avoidable Cost in Drugs for the Treatment of Rheumatoid Arthritis: Beneficio económico de los ensayos clínicos controlados patrocinados: El gasto evitable en medicamentos para el tratamie |
Search more.